THYROCARENSEThyrocare Technologies LimitedMediumNeutral
Announced Thu, 7 May · 20:08 IST

Thyrocare Technologies Limited has informed the Exchange regarding Change in Auditors of the company.

Multiple Ind Directors ResignedPromoter Family Board EntryManagement Changes View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.3%1-day move
₹472.50
prior close
₹493.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9
Up moveDown movePending
AI summary

Thyrocare Technologies held a board meeting on May 7, 2026, approving several key matters. The company recommended a final dividend of Rs. 7 per share for FY 2025-26, taking total dividend to Rs. 9.33 per share (post bonus adjustment). Statutory auditors will change from M S K A & Associates LLP to Price Waterhouse Chartered Accountants LLP for a 5-year term, with the existing auditors completing their tenure. Two Non-Executive Non-Independent Directors resigned citing pre-occupation (Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah), while two new directors (Uday Patel Kadam and Gaurav Verma) were appointed. CEO Rahul Franklin Guha was re-appointed for 5 years. The company also approved up to Rs. 5.5 crore investment in its wholly owned subsidiary Think Health Diagnostics and proposed amendments to its Memorandum of Association to expand healthcare activities.

Likely market impact

The resignation of two directors on the same day and appointment of two new directors from API Holdings indicates significant board restructuring. Shareholders should note the upcoming auditor change and expanded business scope proposals.